Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Study Overview
=================
Brief Summary
-----------------
This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous System) systemic embolism prevention in patients with AF (Atrial fibrillation) and prior stroke or TIA (Transient Ischemic attack) who treat with rivaroxaban at an initial visit and three follow-up visits.

Official Title
-----------------
Prospective Multicenter Observational Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Conditions
-----------------
Stroke, Embolism

Intervention / Treatment
-----------------
* Other: Rivaroxaban ( Xarelto, BAY59-7939)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients ≥ 18 years old who start treatment with rivaroxaban Non-valvular Atrial Fibrillation is documented in patients' file Prior TIA/Stroke history TIA - more than 72 hours after documented TIA more than 2 weeks after non-hemorrhagic stroke Written informed consent Exclusion Criteria: Contraindications for use of Xarelto® in accordance with approved product label Previous thromboprophylaxis treatment with anticoagulants prior toby reason of stroke / TIA prevention Any reasons of medical and non-medical character, which in the opinion of the physician can hamper patient participation in NIS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Other: Rivaroxaban ( Xarelto, BAY59-7939)<br>* Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prescription pattern of neurologists in secondary stroke or non-CNS systemic embolism prevention in patients with AF and prior stroke or TIA who treat with rivaroxaban | Time lag after prior stroke or TIA before Xarelto prescription; Frequency of switching/discontinuation of Xarelto treatment; Time to switching/discontinuation of Xarelto treatment; Reasons of switching/discontinuation of Xarelto treatment (using formalized criteria list); In case of change of treatment - drug, dose, duration of use | up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Descriptive characteristics of patients after prior stroke/TIA in the need of secondary stroke prevention with Xarelto (gender, age, race, alcohol/smoking, BMI and BP abnormalities, CHA2DS2 VASC, HAS BLED, Rankin Score) | CHA2DS2 VASC - Stroke risk assessment scale; HAS BLED - Score for Major Bleeding Risk (in anticoagulation therapy) | up to 6 months | 
| Identify time of start of anticoagulation therapy immediately after event (stroke or TIA) for secondary prevention in real life practice |  | up to 6 months | 
| Describe AE characteristics (frequency, severity, relation to treatment, AE treatment, AE outcome) |  | up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rivaroxaban, Non-interventional, Prevention in prior stroke or TIA, Russian Federation